A Comparative Study of the Efficacy and Safety of Telitacicept and Belimumab in the Treatment of Systemic Lupus Erythematosus Involving Multiple Units, Based on Previous Data.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Yipeng Liu
With
Renmin Hospital of Wuhan University
Affiliated Hospital of Shandong University of Traditional Chinese Medicine
Beijing Friendship Hospital
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age range: 18 - 65 years old;
Meets the revised SLE classification criteria of the American College of Rheumatology in 1997 or the SLE diagnostic classification criteria issued by EULAR/ACR in 2019;
SELENA-SLEDAI score of at least 8 points (clinical symptoms of no less than 6 points, excluding positive anti-double-stranded DNA (anti-dsDNA) and low complement);
Patients who have been using tofacitinib or belimumab for at least 12 weeks.
You may not be if
Having active central nervous system diseases;
eGFR \< 30 mL/min/1.73m², or undergoing hemodialysis or kidney transplantation;
Pregnant women, or women planning to get pregnant in the near future while taking the medication, or lactating women;
Participants who are simultaneously participating in other clinical studies;
Patients who have received treatment with tixagrel or belimumab for less than 12 weeks.
Clareo Health | A Comparative Study of the Efficacy and Safety of Telitacicept and Belimumab in the Treatment of Systemic Lupus Erythematosus Involving Multiple Units, Based on Previous Data.
